Minimal Phototoxic Dose for Vitiliginous Skin Lesions.
- Author:
Hyup KIM
1
;
Jang Kyu PARK
;
Young Joon SEO
;
Jeung Hoon LEE
Author Information
1. Department of Dermatology, Chungnam National University College of Medicine Daejon, Korea. parkjk@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Minimal phototoxic dose;
Photochemotherapy;
Vitiligo
- MeSH:
Humans;
Methoxsalen;
Photochemotherapy;
Seasons;
Skin*;
Vitiligo
- From:Korean Journal of Dermatology
2004;42(8):983-987
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Photochemotherapy (PUVA) is the effective treatment for vitiligo. It is necessary to measure the minimal phototoxic dose (MPD) in order to ascertain a safe, effective UVA dose needed for irradiation during photochemotherapy. OBJECTIVE: The purpose of this study was to standardize the MPD for vitiliginous lesions. METHOD: The MPD was measured in 124 vitiligo patients. The number of patients monitored for topical and systemic MPD using the photosensitiser, 8-methoxypsoralen (8-MOP) were 41 and 83, respectively. MPD was also analysed according to sex, age, site of the vitiliginous lesions, duration of disease, season and administration route of the photosensitiser. RESULTS: 1. In the group assessed for topical application of 8-MOP cream, mean MPD was 0.62+/-0.59J/cm2. 2. In the group assessed for systemic administration of 8-MOP, mean MPD was 2.68+/-1.83J/cm2. 3. MPD in the group systemically administrated with 8-MOP was 4.32-fold to that of the topical application group (p<0.01). 4. In the case of both topical and systemic administration of the photosensitiser, 8-MOP, no significant differences in MPD were found due to the sex, age, site of vitiliginous lesions, duration of disease, or season in which MPD was administered to patients. CONCLUSION: There was a significant difference in MPD between the topical application group and the systemic administration group.
